Etanercept Therapy for Nails Psoriasis Monitoring With Noninvasive Imaging

• Status: Recruiting
• Trial end date: 2022-08-08
• Target enrollment: 0
• Participant gender: All

Summary

OptiSkin is now enrolling a new study to monitor nail changes in patients with nail psoriasis treated with Enbrel® (etanercept) with optical coherence tomography (OCT).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: OptiSkin Medical
• Collaborator: Amgen
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• Moderate to severe psoriasis

• Psoriasis affecting the fingernails

Exclusion Criteria:

• Previous treatment with Enbrel® (etanercept)

• Active infection

• Rheumatoid arthritis

• Any personal or family history of any neurologic demyelinating disease

• Receipt of investigational drugs or "biologics" within 4 weeks of the screening visit